Health Affairs' Senior Deputy Editor Rob Lott interviews Jihye Han of Brigham and Women's Hospital and Harvard University on her recent paper that takes a closer look at the regulatory treatments for ...

Researchers looked specifically at head-to-head randomized clinical trials of next-in-class cancer drugs against existing agents in the same class. Less than one-quarter of next-in-class cancer drugs ...

Aromatase Inhibitor Drug Class Market To Reach USD$ 6.7 Billion By 2033 Growth Drivers, Forecast & Industry (2026). EINPresswire/ -- Market Size and Growth (2026) According to DataM Intelligence, the ...

Add Yahoo as a preferred source to see more of our stories on Google. Nitazenes, like this powder sample, are a class of synthetic opioids more potent than morphine and fentanyl. Joe Lamberti/The ...

Hyperactive signaling pathways of some aggressive blood cancer cells can be tamped down by a previously unrecognized protein complex, ensuring the cancer's survival. If one component of the complex is ...

Scientists at the University of Lausanne (UNIL) and University center Unisanté classified 35 commonly used drugs in Switzerland based on their impact on the aquatic biodiversity. Scientists at the ...

This Nature Outlook is editorially independent, produced with financial support from Avadel. Miranda cannot remember a time in her life when she did not have insomnia. The 23 year old, who asked for ...

Following a warning by a UK regulator about a small risk of severe acute pancreatitis with weight loss jabs, Medical News Today spoke to 3 experts about who is most at risk and whether the benefits ...

In 22.2% of trials, there was a survival benefit with the next-in-class agent. Less than one-quarter of next-in-class cancer drugs demonstrated a survival benefit over existing in-class agents in head ...